779999-14-3

Basic information

• Product Name: PIPERIDINE-4-CARBOXYLIC ACID PYRIDIN-3-YLAMIDE
• Synonyms: PIPERIDINE-4-CARBOXYLIC ACID PYRIDIN-3-YLAMIDE;N-(Pyridin-3-yl)piperidine-4-carboxamide
• CAS NO: 779999-14-3
• Molecular Formula: C11H15N3O
• Molecular Weight: 205.26
• Mol File: 779999-14-3.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 427.126 °C at 760 mmHg
• Flash Point: 212.118 °C
• Appearance: /
• Density: 1.178 g/cm³
• PKA: 13.65±0.20(Predicted)
• CAS DataBase Reference: PIPERIDINE-4-CARBOXYLIC ACID PYRIDIN-3-YLAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: PIPERIDINE-4-CARBOXYLIC ACID PYRIDIN-3-YLAMIDE(779999-14-3)
• EPA Substance Registry System: PIPERIDINE-4-CARBOXYLIC ACID PYRIDIN-3-YLAMIDE(779999-14-3)

Safety Data

• Hazardous Substances Data: 779999-14-3(Hazardous Substances Data)

Usage

General Description

PIPERIDINE-4-CARBOXYLIC ACID PYRIDIN-3-YLAMIDE is a chemical compound that consists of a piperidine ring with a carboxylic acid group and a pyridine-3-ylamide moiety. It is commonly used in organic synthesis and pharmaceutical research as a building block for the preparation of various bioactive compounds. PIPERIDINE-4-CARBOXYLIC ACID PYRIDIN-3-YLAMIDE has been studied for its potential pharmacological properties, including anti-tumor, anti-inflammatory, and antiviral activities. Its unique structure and versatile reactivity make it a valuable tool in the development of new drugs and chemical agents.

Upstream product

• 462-08-8 pyridin-3-ylamine 
• 84358-13-4 N-[(tert-butoxy)carbonyl]piperidine-4-carboxylic acid 

Relevant articles and documents

Covalent docking modelling-based discovery of tripeptidyl epoxyketone proteasome inhibitors composed of aliphatic-heterocycles

The potential of specific proteasome inhibitors to act as anti-cancer agents has attracted intensive investigations. The proteasome can be covalently inhibited by epoxyketone derivatives via a two-step reaction. Several computational approaches have been developed to mimic the covalent binding event. Compound 1 composed of a six-membered heterocyclic ring was designed by using covalent docking. With a possible different binding mode from the clinical compound Carfilzomib, it occupied the S5 pocket of 20S proteasome and showed favorable inhibitory activity. Subsequently optimization and evaluation were taken place. Among these compounds, 11h demonstrated extraordinary in vitro inhibitory activity and selectivity, and good in vivo proteasome inhibitory activity, a favorable pharmacokinetic profile and xenograft tumor inhibition. The possible binding pattern of compound 11h against proteasome was further fully explored via calculations, providing a theoretical basis for finding potent proteasome inhibitors.

Preventives/remedies for kidney diseases

A compound having a Rho kinase inhibitory activity, such as (+)-trans-4-(1-aminoethyl)-1-(4-pyridylcarbamoyl)-cyclohexane, has a renal interstitial fibrosis inhibitory action in renal interstitial fibrosis model mice and various other actions, and therefore, is useful as an agent for the prophylaxis or treatment of renal diseases.

Agent for prophylaxis and treatment of glaucoma

An agent for the prophylaxis and treatment of glaucoma, which contains a compound having a Rho kinase inhibitory activity, particularly an agent for the prophylaxis and treatment of glaucoma, which contains a compound of the formula (I) wherein each symbol is as defined in the specification, as the compound having a Rho kinase inhibitory activity, is provided. The agent for the prophylaxis and treatment of glaucoma of the present invention is a novel agent for the prophylaxis and treatment of glaucoma and has intraocular pressure lowering action, optic disc blood flow improving action and aqueous humor outflow promoting action.